Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, G&E Herbal Biotechnology Co's Enterprise Value is NT$1,797.3 Mil.
G&E Herbal Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$67.0 Mil. Therefore, G&E Herbal Biotechnology Co's EV-to-FCF for today is 26.83.
The historical rank and industry rank for G&E Herbal Biotechnology Co's EV-to-FCF or its related term are showing as below:
ROCO:4911'
s EV-to-FCF Range Over the Past 10 Years
Min: -457 Med: -55.32 Max: 5963.27
Current: 26.83
During the past 13 years, the highest EV-to-FCF of G&E Herbal Biotechnology Co was 5963.27. The lowest was -457.00. And the median was -55.32.
ROCO:4911's EV-to-FCF is ranked worse than 63.39% of 336
companies
in the Biotechnology industry
Industry Median: 15.295
vs ROCO:4911: 26.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
G&E Herbal Biotechnology Co (ROCO:4911) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
G&E Herbal Biotechnology Co's PE Ratio (TTM) for today is calculated as:
G&E Herbal Biotechnology Co's share price for today is NT$34.85.
G&E Herbal Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.129.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
G&E Herbal Biotechnology Co EV-to-FCF Related Terms
G&E Herbal Biotechnology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4911 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, G&E Herbal Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
G&E Herbal Biotechnology Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, G&E Herbal Biotechnology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where G&E Herbal Biotechnology Co's EV-to-FCF falls into.
G&E Herbal Biotechnology Co's current Enterprise Value is NT$1,797.3 Mil.
G&E Herbal Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$67.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
G&E Herbal Biotechnology Co (ROCO:4911) has a EV-to-FCF of 26.83 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on G&E Herbal Biotechnology Co and its competitors. According to the industry distribution chart, G&E Herbal Biotechnology Co ranks #213 out of 336 companies in the Biotechnology industry, placing it in the top 63.4%.
Is G&E Herbal Biotechnology Co's EV-to-FCF too high?
G&E Herbal Biotechnology Co's current EV-to-FCF is 26.83. The Biotechnology industry median EV-to-FCF is 15.30. G&E Herbal Biotechnology Co's value of 26.83 is 75.4% above this industry median. Based on the distribution chart, G&E Herbal Biotechnology Co ranks #213 out of 336 companies in the Biotechnology industry, which is below the industry midpoint. Overall, G&E Herbal Biotechnology Co has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does G&E Herbal Biotechnology Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, G&E Herbal Biotechnology Co ranks #213 out of 336 companies for EV-to-FCF. This places G&E Herbal Biotechnology Co in the lower half of its industry. The industry median EV-to-FCF is 15.30. G&E Herbal Biotechnology Co's value of 26.83 is 75.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.30, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. G&E Herbal Biotechnology Co's current EV-to-FCF of 26.83 is 75.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on G&E Herbal Biotechnology Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. G&E Herbal Biotechnology Co's current EV-to-FCF is 26.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is G&E Herbal Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, G&E Herbal Biotechnology Co (ROCO:4911) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$86.98, compared to a current price of NT$34.85 — trading 59.9% below its estimated fair value. The current EV-to-FCF is 26.83 and 75.4% above the Biotechnology industry median of 15.30. G&E Herbal Biotechnology Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For G&E Herbal Biotechnology Co (ROCO:4911), the current EV-to-FCF is 26.83 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is G&E Herbal Biotechnology Co (ROCO:4911) Overvalued in 2026?
Based on GuruFocus' analysis, G&E Herbal Biotechnology Co stock appears to be undervalued.
The current stock price of NT$34.85 is trading 59.9% below its estimated GF Value™ of NT$86.98.
GuruFocus considers G&E Herbal Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:4911:
EV-to-FCF: 26.83
GF Value™: NT$86.98 vs. price of NT$34.85 (59.9% below fair value)
Industry Position: 75.4% above the Biotechnology median (#213 of 336)
No single metric tells the full story. See the ROCO:4911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
G&E Herbal Biotechnology Co Ltd is a Taiwan-based biopharmaceutical company. It specializes in the production of Western conventional drugs, Chinese traditional drugs, unclassified food, cosmetics, and health products. The company is focused on botanical extraction technology and products. Its products include botanical extract toner, total moisture conditioning cream, whitening clear cream, and firming essence cream.
63GF Score
Get the complete analysis for ROCO:4911
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4911 has been successfully added to your 
